NasdaqCM - Nasdaq Real Time Price USD
Cardiff Oncology, Inc. (CRDF)
At close: November 6 at 4:00 PM EST
After hours: 7:49 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
665.0000
488.0000
386.0000
359.0000
366.0000
Gross Profit
244.6320
--
--
--
--
Operating Expense
45,295.0000
45,900.0000
40,288.0000
29,214.0000
19,452.0000
Operating Income
-44,630.0000
-45,412.0000
-39,902.0000
-28,855.0000
-19,086.0000
Net Non Operating Interest Income Expense
3,807.0000
4,069.0000
1,581.0000
264.0000
88.0000
Other Income Expense
-34.0000
-98.0000
-383.0000
300.0000
-309.0000
Pretax Income
-40,857.0000
-41,441.0000
-38,704.0000
-28,291.0000
-19,307.0000
Net Income Common Stockholders
-40,881.0000
-41,465.0000
-38,728.0000
-28,315.0000
-22,598.0000
Diluted NI Available to Com Stockholders
-40,881.0000
-41,465.0000
-38,728.0000
-28,315.0000
-22,598.0000
Basic EPS
-0.92
-0.93
-0.89
-0.73
-1.08
Diluted EPS
-0.92
-0.93
-0.89
-0.73
-1.08
Basic Average Shares
44,714.5000
44,677.0000
43,600.0000
39,030.0000
20,875.0000
Diluted Average Shares
44,714.5000
44,677.0000
43,600.0000
39,030.0000
20,875.0000
Total Operating Income as Reported
-44,630.0000
-45,412.0000
-39,902.0000
-28,855.0000
-19,086.0000
Total Expenses
45,295.0000
45,900.0000
40,288.0000
29,214.0000
19,452.0000
Net Income from Continuing & Discontinued Operation
-40,857.0000
-41,441.0000
-38,704.0000
-28,291.0000
-19,307.0000
Normalized Income
-40,857.0000
-41,441.0000
-38,704.0000
-28,576.0000
-19,026.0000
Interest Income
3,807.0000
4,069.0000
1,581.0000
264.0000
90.0000
Interest Expense
--
--
--
--
2.0000
Net Interest Income
3,807.0000
4,069.0000
1,581.0000
264.0000
88.0000
EBIT
-44,630.0000
-45,412.0000
-39,902.0000
-28,855.0000
-19,305.0000
EBITDA
-44,213.0000
-45,014.0000
-39,666.0000
-28,404.0000
-18,839.0000
Reconciled Depreciation
417.0000
398.0000
236.0000
451.0000
466.0000
Net Income from Continuing Operation Net Minority Interest
-40,857.0000
-41,441.0000
-38,704.0000
-28,291.0000
-19,307.0000
Total Unusual Items Excluding Goodwill
--
--
--
285.0000
-281.0000
Total Unusual Items
--
--
--
285.0000
-281.0000
Normalized EBITDA
-44,213.0000
-45,014.0000
-39,666.0000
-28,689.0000
-18,558.0000
12/31/2020 - 7/27/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RVPH Reviva Pharmaceuticals Holdings, Inc.
0.9330
+1.89%
CRVS Corvus Pharmaceuticals, Inc.
8.78
-4.88%
ATRA Atara Biotherapeutics, Inc.
10.01
-2.68%
TPST Tempest Therapeutics, Inc.
1.0400
+4.00%
TERN Terns Pharmaceuticals, Inc.
7.24
+0.98%
SGMO Sangamo Therapeutics, Inc.
2.4700
+14.35%
SLS SELLAS Life Sciences Group, Inc.
1.1600
-1.69%
GNPX Genprex, Inc.
1.5500
-14.36%
ZNTL Zentalis Pharmaceuticals, Inc.
3.8400
+1.59%
VSTM Verastem, Inc.
3.8700
+3.48%